Indication Tooltip

LORBRENA® (lorlatinib) is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)

  • that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, and
  • that has spread to other parts of the body, and
  • who have taken the medicine:
    • alectinib, or ceritinib, or
    • both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
  • that is no longer responding to these treatments.

It is not known if LORBRENA is safe and effective in children.

The effectiveness of LORBRENA is based on a study that measured tumor response rate and duration of response. There is an ongoing study to find out how LORBRENA works over a longer period of time.

As you begin treatment with LORBRENA, it may be helpful to learn more about what to expect. To help you identify potential side effects, the serious and most common have been outlined below. Be sure to share with your doctor if you experience these or any other side effects. It's important to remember that everyone responds to treatment differently, so you may or may not experience some of the side effects described here.

Side effects while on LORBRENA can usually be managed by your healthcare provider by adjusting your LORBRENA dose, temporarily withholding your dose, or suggesting additional medicine to take while you are taking LORBRENA.

Turn to Pfizer Oncology Together™ to learn about financial assistance resources and get personalized support from one of our dedicated Care Champions.